definiens: means, as of the Effective Date and i rrespective of whether such requires regulatory approval, ( i ) the enhanced production and purificat ion of non - genetically modified human autologous fibroblasts for use in all aesthetic and therapeutic indications ; ( ii ) the enhanced production and purification of non - genetically modi fied human autologous dermal cells for use in aesthetic and therapeutic treatment of dermal, voca l cord, and periodontal indications ; ( iii ) the development of genetically modified autologous huma n fibroblasts for use in all aesthetic and therapeutic indications where an autologous fibrobl ast itself is the principal effector of the product in contrast to the use of autologous fibroblasts as th e source of expression of a systemically available therapeutic protein in which that protein ( and not the fibroblast per se ) is the principal therapeutic effector ; ( iv ) the development of genetically modif ied autologous human dermal cells for aesthetic and therapeutic treatment of dermal, vocal cord, an d periodontal indications ; ( v ) autologous human fibroblasts genetically modified to express a thera peutic protein and/or bioactive RNA for the treatment of autoimmune and non - infectious inflamma tory disorders that manifest in cutaneous tissues, fascia and/or muscle, and ( vi ) autologous human fibroblasts genetically modified to express bioactive Tenascin X locally to correct connective tissue disorders . For clarity, the does not include inductive pluripotent cell products that ar e derived from autologous fibroblasts or dermal cells or products that are subject to an existing I ntrexon collaboration . ” 2 . In partial consideration for the additional righ ts granted to Fibrocell hereunder, Fibrocell shall issue to [COMPANY], as an additional access fee for commercia l license rights to the [COMPANY] IP granted hereund er, certain shares of the common stock of Fibrocell ( th e ) . The Supplemental Access Fee will be that number of shares of Fibroce ll common stock ( the ) having a value equaling approximately $ 5,0 00,000, and such shares ’ issuance will occur pursuant to the terms of a Supplemental Stock Issua nce Agreement of even date herewith ( the ) . Provided that all closing conditions f or the Supplemental Access Fee Shares ( as defined in the Issuance Agreement ) that are within the reas onable control of [COMPANY] have been satisfied or waived, the issuance of the Supplemental Access Fee Shares is a condition subsequent to the effectiveness of this Amendment